<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Circulating subclinical <z:chebi fb="0" ids="16412">lipopolysaccharide</z:chebi> (LPS) occurs in health and disease </plain></SENT>
<SENT sid="1" pm="."><plain>Ingesting high fatty meals increases LPS that cause metabolic endotoxemia </plain></SENT>
<SENT sid="2" pm="."><plain>Subclinical LPS in <z:e sem="disease" ids="C0031090" disease_type="Disease or Syndrome" abbrv="">periodontal disease</z:e> may impair endothelial function </plain></SENT>
<SENT sid="3" pm="."><plain>The heart may be targeted as cardiac cells express TLR4, the LPS receptor </plain></SENT>
<SENT sid="4" pm="."><plain>It was hypothesized that recurrent exposure to subclinical LPS increases mortality and causes <z:mp ids='MP_0003141'>cardiac fibrosis</z:mp> </plain></SENT>
<SENT sid="5" pm="."><plain>METHODS: C57Bl/6 mice were injected with intraperitoneal saline (control), low dose LPS (0.1 or 1 mg/kg), or moderate dose LPS (10 or 20 mg/kg), once a week for 3 months </plain></SENT>
<SENT sid="6" pm="."><plain>Left ventricular (LV) function (echocardiography), hemodynamics (tail cuff pressure) and electrocardiograms (telemetry) were measured </plain></SENT>
<SENT sid="7" pm="."><plain><z:mp ids='MP_0003141'>Cardiac fibrosis</z:mp> was assessed by picrosirius red staining and LV expression of <z:mp ids='MP_0003045'>fibrosis</z:mp> related genes (QRT-PCR) </plain></SENT>
<SENT sid="8" pm="."><plain>Adult cardiac fibroblasts were isolated and exposed to LPS </plain></SENT>
<SENT sid="9" pm="."><plain>RESULTS: LPS injections transiently <z:mp ids='MP_0002626'>increased heart rate</z:mp> and blood pressure (&lt;6 hours) and mildly decreased LV function with full recovery by 24 hours </plain></SENT>
<SENT sid="10" pm="."><plain>Mice tolerated weekly LPS for 2-3 months with no change in activity, appearance, appetite, weight, blood pressure, LV function, oximetry, or blood chemistries </plain></SENT>
<SENT sid="11" pm="."><plain>Mortality increased after 60-90 days with moderate, but not low dose LPS </plain></SENT>
<SENT sid="12" pm="."><plain><z:hpo ids='HP_0011675'>Arrhythmias</z:hpo> occurred a few hours before <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="13" pm="."><plain>LV collagen fraction area increased dose-dependently from 3.0±0.5% (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SEM</z:e>) in the saline control group, to 5.6±0.5% with low dose LPS and 9.7±0.9% with moderate dose LPS (P&lt;0.05 moderate vs low dose LPS, and each LPS dose vs control) </plain></SENT>
<SENT sid="14" pm="."><plain>LPS increased LV expression of collagen Iα1, collagen IIIα1, MMP2, MMP9, TIMP1, periostin and IL-6 (P&lt;0.05 moderate vs low dose LPS and vs control) </plain></SENT>
<SENT sid="15" pm="."><plain>LPS increased α-SMA immunostaining of myofibroblasts </plain></SENT>
<SENT sid="16" pm="."><plain>LPS dose-dependently increased IL-6 in isolated adult cardiac fibroblasts </plain></SENT>
<SENT sid="17" pm="."><plain>CONCLUSIONS: Recurrent exposure to subclinical LPS increases mortality and induces <z:mp ids='MP_0003141'>cardiac fibrosis</z:mp> </plain></SENT>
</text></document>